AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27389243
Drug: Warfarin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (100 U/kg)
Trial: 24668660
Drug: Warfarin (control)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (control)
Trial: 23034540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise training and β-blockade
Trial: 20948520
Drug: Large portion
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large portion (820 g of pasta)
Trial: 20948520
Drug: Small portion
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small portion (410 g of pasta)
Trial: 16023759
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin therapy (150mg daily for 14 days)
Trial: 16023759
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin therapy
Trial: 12827577
Drug: Aspirin ingestion
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin ingestion within 7 days of surgery
Trial: 12827577
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin ingestion
Trial: 12827577
Drug: Central venous
RxNorm normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central venous or peripheral venous infusion of protamine
Trial: 9763056
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg (2x200 mg) once daily for 5 days
Trial: 7874847
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone with resistance exercise for 10 weeks
Trial: 28190761
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (FEC-DOC and DOC-C)
Trial: 20667273
Drug: Foveal presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foveal presentation with no concurrent task
Trial: 20667273
Drug: Foveal presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foveal presentation with concurrent task
Trial: 15022575
Drug: Xiclav (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiclav (amoxicillin + clavulanic acid) administered parenterally i.v. (adults at a dose of 3 x 1.2 gr i.v.; children at a dose of 3 x 30 mg/kg) with early oral switch therapy (adults at a dose of 3 x 625 mg per os; children at a dose of 3 x 25‐50 mg/kg)
Trial: 15022575
Drug: Parenteral regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral regimen without transition to oral dosage form
Trial: 8676798
Drug: Pyridoxine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (70 mg/day)
Trial: 22328739
Drug: BMS945429 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS945429 (80 mg)
Trial: 22328739
Drug: BMS945429 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS945429 (160 mg)
Trial: 22328739
Drug: BMS945429 (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS945429 (320 mg)
Trial: 21049175
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy (duration: 1 to 7 years)
Trial: 17034006
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean dose 119.2 +/- 56.4 mg)
Trial: 16274152
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (implants restored after a healing period)
Trial: 11898006
Drug: Rush immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rush immunotherapy (RIT) with IFA whole body extract (WBE)
Trial: 11898006
Drug: Rush immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rush immunotherapy (RIT) with IFA WBE
Trial: 7583862
Drug: Theo-24 (anhydrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-24 (anhydrous extended-release capsules) plus inhaled beta 2-agonist
Trial: 7583862
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus inhaled beta 2-agonist
Trial: 347106
Drug: Levamisole as
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole as an immune adjuvant in addition to standard therapy
Trial: 31734121
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g × 2 whey-enriched protein supplementation
Trial: 31083000
Drug: Propofol total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol total intravenous anaesthesia combined with desflurane anaesthesia
Trial: 25427288
Drug: Incisional Local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional Local Anesthetic Administration (port infiltration) with ropivacaine 0.5%
Trial: 12739685
Drug: Periodontal ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal ligament injection (PDLi) with a computerized device (Wand)
Trial: 12739685
Drug: Conventional buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional buccal infiltration
Trial: 11142541
Drug: Social Effectiveness
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Effectiveness Therapy for Children (SET-C)
Trial: 4061524
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (600 mg of calcium L-aspartate daily)
Trial: 30529244
Drug: COPE (Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Trial: 29878826
Drug: Team treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team treatment milieu
Trial: 24839984
Drug: Silica gel
RxNorm normalized name: Silica gel
DrugBank: Silicon dioxide (DB11132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silica gel fibre (SGF) in addition to standard treatment
Trial: 24839984
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment (S-o-C) alone
Trial: 17285423
Drug: MgSO(4) 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO(4) 40 mg.kg(‐1)
Trial: 15642806
Drug: Vision therapy/orthoptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vision therapy/orthoptics
Trial: 15642806
Drug: Placebo vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vision therapy/orthoptics
Trial: 12119223
Drug: GM-CSF (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (3 mcg/kg intravenous daily for 5 days)
Trial: 10466241
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (letrozole, anastrazole)
Trial: 10466241
Drug: LH-RH agonists
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH agonists
Trial: 10466241
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy regimens (CMF or CAF)
Trial: 7473906
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg via enteral route
Trial: 7473906
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg via intravenous (IV) route
Trial: 2258807
Drug: Topical nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonsteroidal anti-inflammatory agent (0.03% flurbiprofen)
Trial: 2258807
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (1% prednisolone acetate)
Trial: 7029684
Drug: Razoxane (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Razoxane (125 mg twice daily for 5 consecutive days every week indefinitely)
Trial: 27140802
Drug: Separate-tablet regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate-tablet regimen (EVG 150mg + COBI 150mg + FTC/TDF 200mg/300mg)
Trial: 27140802
Drug: Single-tablet regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tablet regimen (EVG/COBI/FTC/TDF)
Trial: 23632659
Drug: BZA/CE treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA/CE treatment
Trial: 19475630
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral mecamylamine
Trial: 19475630
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg oral mecamylamine
Trial: 19475630
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg oral mecamylamine
Trial: 19025429
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day with prasugrel (60 mg loading dose followed by 10 mg/day)
Trial: 19025429
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day with clopidogrel (300 mg loading dose followed by 75 mg/day)
Trial: 19025429
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day with prasugrel or clopidogrel
Trial: 10432470
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methylphenidate (0.28 mg/kg)
Trial: 10432470
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylphenidate (0.56 mg/kg)
Trial: 10432470
Drug: Baseline (off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (off drug)
Trial: 8853523
Drug: New anti-cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anti-cancer agents in phase II studies
Trial: 8853523
Drug: New anti-cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anti-cancer agents in phase III studies
Trial: 8853523
Drug: New anti-cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anti-cancer agents in phase IV studies
Trial: 6990475
Drug: 14-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-valent pneumococcal capsular polysaccharide vaccine (Pn)
Trial: 6990475
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b capsular polysaccharide vaccine (Hib)
Trial: 27355577
Drug: Repetitive transorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transorbital alternating current stimulation (rtACS) for 50 min daily for 10 days
Trial: 27355577
Drug: Sham-stimulation for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-stimulation for 50 min daily for 10 days
Trial: 20395940
Drug: L-NMMA infusion
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA infusion after ischemia at wrist level for 1 minute
Trial: 20395940
Drug: L-NMMA infusion
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA infusion after ischemia at wrist level for 2 minutes
Trial: 20395940
Drug: L-NMMA infusion
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA infusion after ischemia at wrist level for 5 minutes
Trial: 20395940
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion after ischemia at upper arm
Trial: 10408999
Drug: Awareness group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness group (received specific informational brochures on diet and cardiovascular risk factors and the reasons for the treatment)
Trial: 1932649
Drug: Bovine lung
RxNorm normalized name: defibrotide, bovine lung
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lung heparin (BLH)
Trial: 1932649
Drug: Porcine mucosal
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine mucosal heparin (PMH)
Trial: 7333749
Drug: High blood
RxNorm normalized name: Cough & Cold High Blood Pressure Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High blood glucose (G)
Trial: 18972125
Drug: Skin protection
RxNorm normalized name: NeutrapHor 1% Skin Protection Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin protection and skin care in combination
Trial: 17060516
Drug: 2.0-g extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0-g extended-release azithromycin microspheres (single-dose regimen)
Trial: 17060516
Drug: 500-mg immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg immediate-release azithromycin tablet (3-day regimen)
Trial: 23593417
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg twice daily
Trial: 11684346
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not taking aspirin
Trial: 11684346
Drug: Patients taking
RxNorm normalized name: Lamictal Blue (For Patients Taking Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients taking aspirin
Trial: 2907898
Drug: Protocol I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol I: 7 injections of 1,500 IU hCG every other day
Trial: 2907898
Drug: Protocol II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol II: 4 injections of 100 IU/kg hCG at 4- to 5-day intervals
Trial: 24748286
Drug: Intra-articular PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular PRP injections (3 injections at monthly intervals)
Trial: 24748286
Drug: Intra-articular PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular PRP injections (2 cycles of 3 injections)
Trial: 16490513
Drug: Ibopamine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 2% solution administered as eyedrops
Trial: 17974698
Drug: Cell infusion
RxNorm normalized name: irrigation set MISCELL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell infusion
Trial: 11735095
Drug: Association with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association with concurrent diseases
Trial: 3311687
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg) and Pirenzepine (50 mg) at bed-time
Trial: 3311687
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg) and Placebo at bed-time
Trial: 27385430
Drug: Medication organisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication organisation devices (MODs) supplied either weekly or monthly
Trial: 27385430
Drug: Medication organisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication organisation devices (MODs)
Trial: 27385430
Drug: MOD monthly
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: MOD monthly
Trial: 23532993
Drug: Behaviorally focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally focused maintenance treatment (MT)
Trial: 23532993
Drug: Socially focused
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Socially focused maintenance treatment (MT)
Trial: 11168739
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg 2x daily for 12 weeks
Trial: 11168739
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg 1x daily in part III
Trial: 26230671
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day intranasal glutathione
Trial: 26230671
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day intranasal glutathione
Trial: 24124993
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (CIMT at home)
Trial: 24124993
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical and occupational therapy (therapy as usual)
Trial: 17157113
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir morning injection
Trial: 17157113
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir evening injection
Trial: 17157113
Drug: NPH evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NPH evening injection
Trial: 10891736
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg with 2 g of amoxicillin and 1 g of clarithromycin for 10 days
Trial: 10891736
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg with 2 g of amoxicillin and 1 g of clarithromycin for 7 days
Trial: 10891736
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg with 2 g of amoxicillin and 1 g of clarithromycin for 10 days
Trial: 10891736
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg with 2 g of amoxicillin and 1 g of clarithromycin for 7 days
Trial: 8922877
Drug: ZK 136295
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 136295 (60 micrograms i.v. and 120/240 micrograms oral)
Trial: 8922877
Drug: ZK 115194
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 115194 (60 micrograms i.v. and 240 micrograms oral)
Trial: 8922877
Drug: Ethinylestradiol (EE2)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol (EE2) (60 micrograms i.v. and 120/240 micrograms oral)
Trial: 1348771
Drug: Handrub with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handrub with 2 portions of 3 ml of 2-propanol 60% v/v for 1 min
Trial: 29696420
Drug: Dexamethasone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (3 daily 8-mg doses starting 48 hours before bleaching)
Trial: 29696420
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 daily doses starting 48 hours before bleaching)
Trial: 26673440
Drug: Guideline-oriented medical
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-oriented medical treatment
Trial: 26673440
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (carotid endarterectomy or carotid artery stenting)
Trial: 24850625
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/d of zinc sulfate, 10 mg/d of iron, and 0.5 mg/d of copper)
Trial: 24850625
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 mg/d of iron and 0.5 mg/d of copper)
Trial: 21961763
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy for Command Hallucinations + Treatment as Usual
Trial: 17688659
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg twice daily for 12 weeks
Trial: 7772354
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl patch (75 micrograms/hr) for 72 hours
Trial: 6771814
Drug: Cloxazolam as
RxNorm normalized name: cloxazolam
DrugBank: Cloxazolam (DB01553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxazolam as a tranquilizer